Results 1 to 10 of about 3,802,616 (346)

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

Nature, 2021
The SARS-CoV-2 B.1.1.529 (Omicron) variant contains 15 mutations of the receptor-binding domain (RBD). How Omicron evades RBD-targeted neutralizing antibodies requires immediate investigation.
Yunlong Cao, Jing Wang, F. Jian, T. Xiao, Weiliang Song, A. Yisimayi, Weijing Huang, Qian-qian Li, Peng Wang, R. An, Jing Wang, Yao Wang, Xiaowei Niu, Sijie Yang, Huitong Liang, Haiyan Sun, Taojing Li, Yuanling Yu, Qianqian Cui, Shuo Liu, Xiaodong Yang, Shuo Du, Zhiying Zhang, Xiaohua Hao, Fei Shao, R. Jin, Xiangxi Wang, Junyu Xiao, Youchun Wang, X. Xie   +29 more
semanticscholar   +1 more source

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection

Nature, 2022
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages BA.2.12.1, BA.4 and BA.5 exhibit higher transmissibility than the BA.2 lineage1.
Yunlong Cao, A. Yisimayi, F. Jian, Weiliang Song, T. Xiao, Lei Wang, Shuo Du, Jing Wang, Qian-qian Li, Xiaosu Chen, Yuanling Yu, Peng Wang, Zhiying Zhang, Pulan Liu, R. An, Xiaohua Hao, Yao Wang, Jing Wang, Rui Feng, Haiyan Sun, Li-Jin Zhao, Wen Zhang, Dong Zhao, Jiang Zheng, Lingling Yu, Can Li, Na Zhang, Rui Wang, Xiaowei Niu, Sijie Yang, Xuetao Song, Yangyang Chai, Ye Hu, Yan-mei Shi, Linlin Zheng, Zhiqiang Li, Qingqing Gu, Fei Shao, Weijing Huang, R. Jin, Zhongyang Shen, Youchun Wang, Xiangxi Wang, Junyu Xiao, X. Xie   +44 more
semanticscholar   +1 more source

Acknowledgment to the Reviewers of Antibodies in 2022

Antibodies, 2023
High-quality academic publishing is built on rigorous peer review [...]
Antibodies Editorial Office
doaj   +1 more source

Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies

bioRxiv, 2021
The evolution of SARS-CoV-2 could impair recognition of the virus by human antibody-mediated immunity. To facilitate prospective surveillance for such evolution, we map how convalescent serum antibodies are impacted by all mutations to the spike’s ...
Allison J. Greaney, Andrea N. Loes, K. H. Crawford, Tyler N. Starr, Keara D. Malone, H. Chu, J. Bloom   +6 more
semanticscholar   +1 more source

Acknowledgment to Reviewers of Antibodies in 2021

Antibodies, 2022
Rigorous peer-reviews are the basis of high-quality academic publishing [...]
Antibodies Editorial Office
doaj   +1 more source

Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19

New England Journal of Medicine, 2020
Coagulopathy in Critical Illness with Covid-19 The authors describe a 69-year-old man with Covid-19 diagnosed in January 2020 in Wuhan, China, along with two other critically ill patients with Covid-19 who were also seen in the same intensive care unit ...
Yan Zhang, M. Xiao, Shulan Zhang, P. Xia, W. Cao, Wei Jiang, Huan Chen, X. Ding, Hua Zhao, Hongmin Zhang, Chun-yao Wang, Jing Zhao, Xuefeng Sun, R. Tian, Wei Wu, Dong Wu, Jie Ma, Yu Chen, D. Zhang, Jing Xie, Xiaowei Yan, Xiang Zhou, Zheng-yin Liu, Jinglan Wang, B. Du, Yan Qin, P. Gao, X. Qin, Yingchun Xu, Wen Zhang, Taisheng Li, Fengchun Zhang, Yongqiang Zhao, Yongzhe Li, Shuyang Zhang   +34 more
semanticscholar   +1 more source

Acknowledgment to Reviewers of Antibodies in 2020

Antibodies, 2021
Peer review is the driving force of journal development, and reviewers are gatekeepers who ensure that Antibodies maintains its standards for the high quality of its published papers [...]
Antibodies Editorial Office
doaj   +1 more source

Neutralizing monoclonal antibodies for treatment of COVID-19

Nature reviews. Immunology, 2021
Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical trials.
P. Taylor, A. Adams, M. Hufford, I. de la Torre, K. Winthrop, R. Gottlieb   +5 more
semanticscholar   +1 more source

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Science, 2020
Sites of vulnerability in SARS-CoV-2 Antibodies that neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could be an important tool in treating coronavirus disease 2019 (COVID-19). Brouwer et al.
P. Brouwer, Tom G. Caniels, K. van der Straten, Jonne L. Snitselaar, Y. Aldon, S. Bangaru, J. Torres, Nisreen M. A. Okba, M. Claireaux, G. Kerster, A. Bentlage, M. M. van Haaren, Denise Guerra, J. Burger, Edith E. Schermer, K. Verheul, N. van der Velde, Alex van der Kooi, J. van Schooten, M. V. van Breemen, Tom P. L. Bijl, Kwinten Sliepen, A. Aartse, R. Derking, I. Bontjer, N. Kootstra, W. Wiersinga, G. Vidarsson, B. Haagmans, A. Ward, G. D. de Bree, R. Sanders, M. V. van Gils   +32 more
semanticscholar   +1 more source

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Science, 2020
An antibody cocktail against SARS-CoV-2 There is an urgent focus on antibodies that target the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral spike and prevent the virus from entering host cells. Hansen et al.
A. Baum, Benjamin O. Fulton, Elzbieta Wloga, R. Copin, Kristen E. Pascal, Vincenzo Russo, Stephanie Giordano, Kathryn Lanza, N. Negron, M. Ni, Yi Wei, G. Atwal, A. Murphy, N. Stahl, G. Yancopoulos, C. Kyratsous   +15 more
semanticscholar   +1 more source